This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes assessed in the review that were reported in the paper were: the reduction in the number of deaths from first-ever strokes per 1,000 patients; the reduction in the number of recurrent strokes per 1,000 patients; the increase in haemorrhages per 1,000 patients treated with aspirin therapy; the increase in the risk of haemorrhage during the first days after stroke; the reduction in the mortality rate after 3 months; and the increase in the proportion of patients discharged home for those treated with thrombolytic therapy.
The number of persons to whom the interventions could be reasonably applied was also estimated and reported. This took the eligibility criteria and the number of persons already receiving the intervention under current practice into account.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Evidence for the effectiveness of each intervention was reviewed using the approach of Carter et al. (see Other Publications of Related Interest) , which considers the strength of the evidence, and the size and relevance of the effect.
Methods used to judge relevance and validity, and for extracting data
The authors stated that the approach of Carter et al. also allowed an assessment of the size and relevance of the effect, although the results of the assessment were not reported in the present paper.
Number of primary studies included
At least 11 studies were included in the review, four of them reporting data from the NEMESIS study.
Methods of combining primary studies
It was unclear whether data from different studies were combined.
Investigation of differences between primary studies
Results of the review
Among patients treated with aspirin therapy:
there was a reduction of 9 in the number of deaths from first-ever strokes per 1,000 patients;
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there was a reduction of 7 in the number of recurrent strokes per 1,000 patients; and there were two more haemorrhages per 1,000 patients.
For patients treated with thrombolytic therapy:
there was a 5.8% increase in the risk haemorrhage during the first days after stroke;
there was a 20% reduction in the mortality rate after 3 months; and there was a 12% increase in the proportion of patients discharged home.
With aspirin, it was estimated that an additional 9,153 first-ever stroke patients could be targeted. This number excluded 5% of ischaemic stroke patients likely to have contraindications. Thrombolytic therapy was directed at a conservative 5% of time-eligible patients, meaning that only 256 patients were treated.
Methods used to derive estimates of effectiveness
The authors made assumptions to supplement the results of the review.
Estimates of effectiveness and key assumptions
The interventions were assumed to be operating in a "steady state" (i.e. fully implemented and operating in accordance with efficacy potential). It was also assumed that they were applied to all eligible patients who presented during a 1-year period.
The authors assumed 100% compliance for patients treated with aspirin.
Measure of benefits used in the economic analysis
The measure of benefits used was the number of disability-adjusted life-years (DALYs). The DALYs were estimated using the Dutch disability weights for generic stroke, as used in the Australian Burden of Disease study. The time horizons considered were one year and lifetime. The estimated health benefits were discounted at a rate of 5%. The authors reported some other health outcomes. More specifically, the number of patients needed to avoid one DALY, to avoid one stroke, to avoid one death, and to avoid one person permanently disabled; and the numbers of deaths from first-ever strokes and from recurrent strokes.
Direct costs
The direct costs included in the analysis were those to the health care system (both private and public), as well as those for patients and their carers. However, the authors did not report all the cost categories included in the analysis. The sources of the costs were actual data, obtained from published studies and expert opinion. Some but not all of the resources used were reported separately from the costs, while some unit costs were given in an aggregated manner. The estimated costs were the total and incremental costs one year after the first-ever stroke and for the lifetime of the patient. Considering this latter time horizon, the costs were appropriately discounted at an annual rate of 5%. The price year was 1997.
Statistical analysis of costs
The costs were treated as point estimates (i.e. the data were deterministic).
Indirect Costs
The indirect costs were not included.
of the other studies included in the review were provided. They noted that a specific approach was used to consider the strength of the evidence, and the size and relevance of the effect, although the results of these assessments were not provided. The lack of detail on the methodology and results of the review hampered the internal validity and generalisability of these results to other settings.
Validity of estimate of measure of benefit
DALYs were used as the summary measure of benefit. This seems to have been an appropriate measure as it allows comparisons of the study findings with those from other interventions. However, as the authors acknowledged, the study was limited by the coarseness of the generic disability weights for stroke and the consequent insensitivity of the DALY in capturing quality of life considerations. The estimation of benefits was modelled. The estimated health benefits were appropriately discounted given that a lifetime horizon was considered at analysis.
Validity of estimate of costs
As the authors did not report the cost categories included in the study, only reporting total costs, it was unclear whether all the relevant cost categories and individual costs were considered at analysis. This will hamper the generalisability of the authors' results. The costs were converted into US dollars using appropriate exchange rates. Not all of the resource quantities were reported separately from the costs, which would hinder reflation exercises in other settings. Since the costs were incurred over the lifetime of the patient, future costs were appropriately discounted. The price year was reported, which will aid future inflation exercises. The authors performed probabilistic sensitivity analyses around their incremental cost-utility ratios, but even though they reported that univariate analyses were performed, no details or results of these were given.
